2023
Correlation of a commercial platform’s results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors
Slotkin R, Kyriakides T, Kundu A, Stack G, Sutton R, Gupta S. Correlation of a commercial platform’s results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors. PLOS ONE 2023, 18: e0289713. PMID: 37643190, PMCID: PMC10464955, DOI: 10.1371/journal.pone.0289713.Peer-Reviewed Original ResearchEnhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease
Nakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Chang A, McLemore M, Rassi F, Roback J, Neish A, Fasano R, Stowell S. Enhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease. British Journal Of Haematology 2023, 202: 937-941. PMID: 37287128, PMCID: PMC10751105, DOI: 10.1111/bjh.18899.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCOVID-19 vaccinationAntibody responseCell diseaseSARS-CoV-2 vaccinationIgG immune responseSimilar antibody responsesOptimal vaccination strategyIgG titresIgG responsesVaccination strategiesImmune responseSCD controlsGeneral populationPatientsVaccinationDiseaseResponseCohortTitresShort-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
Madsen J, Holm B, Pérez-Alós L, Bayarri-Olmos R, Rosbjerg A, Fogh K, Pries-Heje M, Møller D, Hansen C, Heftdal L, Hasselbalch R, Hamm S, Frikke-Schmidt R, Hilsted L, Nielsen S, Iversen K, Bundgaard H, Garred P. Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination. Microbiology Spectrum 2023, 11: e04947-22. PMID: 36877077, PMCID: PMC10101069, DOI: 10.1128/spectrum.04947-22.Peer-Reviewed Original ResearchSARS-CoV-2Salivary immunityIgG levelsBNT162b2 vaccinationFirst vaccinationSARS-CoV-2-infected individualsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 vaccinationSARS-CoV-2 IgGSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Prospective observational studyTime pointsSerum IgG levelsHigher IgG levelsSyndrome coronavirus 2Copenhagen University HospitalEffect of vaccinationHealth care professionalsBNT162b2 vaccineHybrid immunitySystemic vaccinationDetectable IgGSalivary IgG
2022
Smoking Status, Nicotine Medication, Vaccination, and COVID-19 Hospital Outcomes: Findings from the COVID EHR Cohort at the University of Wisconsin (CEC-UW) Study
Piasecki T, Smith S, Baker T, Slutske W, Adsit R, Bolt D, Conner K, Bernstein S, Eng O, Lazuk D, Gonzalez A, Jorenby D, D’Angelo H, Kirsch J, Williams B, Nolan M, Hayes-Birchler T, Kent S, Kim H, Lubanski S, Yu M, Suk Y, Cai Y, Kashyap N, Mathew J, McMahan G, Rolland B, Tindle H, Warren G, An L, Boyd A, Brunzell D, Carrillo V, Chen L, Davis J, Deshmukh V, Dilip D, Ellerbeck E, Goldstein A, Iturrate E, Jose T, Khanna N, King A, Klass E, Mermelstein R, Tong E, Tsoh J, Wilson K, Theobald W, Fiore M. Smoking Status, Nicotine Medication, Vaccination, and COVID-19 Hospital Outcomes: Findings from the COVID EHR Cohort at the University of Wisconsin (CEC-UW) Study. Nicotine & Tobacco Research 2022, 25: 1184-1193. PMID: 36069915, PMCID: PMC9494410, DOI: 10.1093/ntr/ntac201.Peer-Reviewed Original ResearchConceptsNicotine replacement therapySARS-CoV-2 vaccinationCOVID-19 patientsCurrent smokersFormer smokersSmoking statusCOVID-19 outcomesICU admissionNRT prescriptionHospital outcomesVaccination statusReplacement therapySevere COVID-19 disease outcomesCOVID-19 clinical outcomesCOVID-19 disease outcomesBetter hospital outcomesOdds of deathBody mass indexElectronic health record dataLarge cohort studyCOVID-19 hospitalizationHealth record dataPotential beneficial effectsU.S. health systemEHR cohortEvaluating clinical effectiveness of SARS‐CoV‐2 vaccine in solid organ transplant recipients: A propensity score matched analysis
Tucker M, Azar MM, Cohen E, Gan G, Deng Y, Palacios C, Malinis M. Evaluating clinical effectiveness of SARS‐CoV‐2 vaccine in solid organ transplant recipients: A propensity score matched analysis. Transplant Infectious Disease 2022, 24: e13876. PMID: 35684932, PMCID: PMC9348300, DOI: 10.1111/tid.13876.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsSARS-CoV-2 infectionOrgan transplant recipientsCritical COVID-19Clinical effectivenessTransplant recipientsVaccine eraVaccinated solid organ transplant recipientsCOVID-19Propensity score-matched cohortSARS-CoV-2 vaccinationSevere coronavirus disease 2019Cause-specific Cox regression modelsCOVID-19-related mortalitySARS-CoV-2 vaccinesSARS-CoV-2 infection ratesCurrent vaccine recommendationsKey preventative strategiesPrimary vaccine seriesRetrospective cohort studyDoses of mRNACox regression modelCoronavirus disease 2019Poisson regression modelsVaccine seriesEffects of SARS-CoV-2 vaccination on blood donation and blood banks in India
Hunain R, Uday U, Rackimuthu S, Nawaz FA, Narain K, Essar MY, Rehman MU, Ahmad S, Butt A. Effects of SARS-CoV-2 vaccination on blood donation and blood banks in India. Annals Of Medicine And Surgery 2022, 78: 103772. PMID: 35573470, PMCID: PMC9090855, DOI: 10.1016/j.amsu.2022.103772.Peer-Reviewed Original ResearchModeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
Pérez-Alós L, Armenteros J, Madsen J, Hansen C, Jarlhelt I, Hamm S, Heftdal L, Pries-Heje M, Møller D, Fogh K, Hasselbalch R, Rosbjerg A, Brunak S, Sørensen E, Larsen M, Ostrowski S, Frikke-Schmidt R, Bayarri-Olmos R, Hilsted L, Iversen K, Bundgaard H, Nielsen S, Garred P. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nature Communications 2022, 13: 1614. PMID: 35347129, PMCID: PMC8960902, DOI: 10.1038/s41467-022-29225-4.Peer-Reviewed Original ResearchConceptsT cell responsesBNT162b2 vaccineAntibody levelsAntibody responseSARS-CoV-2 vaccinationSARS-CoV-2 vaccinesNatural infectionIgG antibody responseGamma interferon releaseChAdOx1-nCoV19First doseIgA responsesIgG levelsVaccine injectionSecond dosePrior infectionVaccineInfectionImmunityCOVID-19Generalized mixed modelDoseTwo-phase responseAgeSexHigh-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells
Chen JS, Chow RD, Song E, Mao T, Israelow B, Kamath K, Bozekowski J, Haynes WA, Filler RB, Menasche BL, Wei J, Alfajaro MM, Song W, Peng L, Carter L, Weinstein JS, Gowthaman U, Chen S, Craft J, Shon JC, Iwasaki A, Wilen CB, Eisenbarth SC. High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. Science Immunology 2022, 7: eabl5652. PMID: 34914544, PMCID: PMC8977051, DOI: 10.1126/sciimmunol.abl5652.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSARS-CoV-2Follicular helper cellsB cell responsesHelper cellsAntibody productionCell responsesSARS-CoV-2 vaccinationB-cell receptor sequencingSevere COVID-19Cell receptor sequencingIndependent antibodiesT cell-B cell interactionsViral inflammationAntiviral antibodiesImmunoglobulin class switchingVirus infectionGerminal centersViral infectionClonal repertoireInfectionAntibodiesClass switchingCOVID-19PatientsAn outbreak of SARS‐CoV‐2 on a transplant unit in the early vaccination era
Roberts SC, Palacios C, Grubaugh ND, Alpert T, Ott IM, Breban MI, Initiative Y, Martinello RA, Smith C, Davis MW, Mcmanus D, Tirmizi S, Topal JE, Azar MM, Malinis M. An outbreak of SARS‐CoV‐2 on a transplant unit in the early vaccination era. Transplant Infectious Disease 2022, 24: e13782. PMID: 34969164, DOI: 10.1111/tid.13782.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Infection prevention practicesSARS-CoV-2 outbreakTransplant unitCOVID-19-associated morbiditySolid organ transplant recipientsSARS-CoV-2 vaccinationPrevention practicesHospital day 18Potential index casesOrgan transplant recipientsInfection prevention behaviorsMonoclonal antibody therapyCOVID-19SARS-CoV-2 clustersHospital staff membersWhole-genome sequencingAsymptomatic patientsTransplant recipientsPositive patientsAtypical presentationImmunocompromised patientsAntibody therapyVaccination eraDisease progression
2021
Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
Lee E, Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, Kruse A, Kessler C, Kruse C, Leavitt A, Lee A, Liebman H, Newland A, Ray A, Tarantino M, Thachil J, Kuter D, Cines D, Bussel J. Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood 2021, 138: 586. PMCID: PMC8701617, DOI: 10.1182/blood-2021-152918.Peer-Reviewed Original ResearchSARS-CoV-2 vaccinesITP exacerbationPre-vaccination baselineBristol-Myers SquibbImmune thrombocytopeniaPlatelet countRescue treatmentDose 2Dose 1Second dosePlatelet decreaseSpeakers bureauSpark TherapeuticsConsultancy feesFirst doseCSL BehringSupport associationsNovo NordiskSARS-CoV-2 vaccinationDiagnosis of ITPAdvisory CommitteeData Safety Monitoring BoardConcurrent autoimmune diseasesMore refractory diseasePrior medical treatmentCerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19
Bikdeli B, Chatterjee S, Arora S, Monreal M, Jimenez D, Krumholz HM, Goldhaber SZ, Elkind MSV, Piazza G. Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. Journal Of The American College Of Cardiology 2021, 78: 408-411. PMID: 34116145, PMCID: PMC8186447, DOI: 10.1016/j.jacc.2021.06.001.Peer-Reviewed Original ResearchConceptsCerebral venous sinus thrombosisSARS-CoV-2 vaccinationVenous sinus thrombosisSinus thrombosisU.S. populationCOVID-19ThrombosisVaccinationSARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
Siegel C, Melmed G, McGovern D, Rai V, Krammer F, Rubin D, Abreu M, Dubinsky M, Ahuja V, Allez M, Ananthakrishnan A, Bernstein C, Braun J, Chowers Y, Colombel J, Danese S, Dignass A, Dotan I, Fleshner P, Gasche C, Gearry R, Ghosh S, Griffiths A, Hanauer S, Hart A, Kaplan G, Kaser A, Kotze P, Koutroubakis I, Kruis W, Lakatos P, Levine A, Lewis J, Lindsay J, Loftus E, Louis E, Lukas M, Magro F, Mahadevan U, Mantzaris G, Moum B, Munkholm P, Ng S, O’Morain C, Oresland T, Panaccione R, Panes J, Pemberton J, Prantera C, Ran Z, Reinisch W, Rogler G, Sandborn W, Sands B, Sartor B, Schölmerich J, Siegmund B, Silverberg M, Sood A, Spinelli A, Steinwurz F, Travis S, Turner D, Tysk C, Vatn M, Vermeire S, Yamamoto T, Yamamoto-Furusho J, Panis Y. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut 2021, 70: 635-640. PMID: 33472895, PMCID: PMC7818789, DOI: 10.1136/gutjnl-2020-324000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSARS-CoV-2 vaccinationInflammatory bowel diseaseInternational Consensus MeetingBowel diseaseConsensus meetingPatientsVaccinationDiseaseNonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection
Chen JS, Alfajaro MM, Chow RD, Wei J, Filler RB, Eisenbarth SC, Wilen CB. Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. Journal Of Virology 2021, 95: 10.1128/jvi.00014-21. PMID: 33441348, PMCID: PMC8092681, DOI: 10.1128/jvi.00014-21.Peer-Reviewed Original ResearchSARS-CoV-2 infectionNonsteroidal anti-inflammatory drugsCOVID-19 pathogenesisSARS-CoV-2Anti-inflammatory drugsProduction of prostaglandinsCyclooxygenase-2Immune responseNSAID treatmentCyclooxygenase-1Enzymes cyclooxygenase-1Inflammatory responseAbility of NSAIDsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSARS-CoV-2 vaccinationViral replicationPro-inflammatory cytokine responseCoronavirus 2 infectionExpression of angiotensinRelief of painPro-inflammatory cytokinesCoronavirus disease 2019 (COVID-19) pandemicHumoral immune response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply